Physician profile
Timothy L Jackson
NPI 1427070747
$1,039.80
in general payments reported to CMS, 2019-2025
26 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $195 · 2021: $95.34 · 2022: $223 · 2023: $111 · 2024: $44.96 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.85 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $315.46 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $159.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $124.13 | 2019-2022 | |
| Astellas Pharma US INC | $72.55 | 2020-2022 | |
| Pfizer INC. | $63.37 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $55.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $48.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $38.41 | 2019-2022 | |
| Recor Medical INC | $28.13 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abbott Laboratories | $21.64 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $20.01 | 2019 | |
| Amgen INC. | $18.71 | 2025 | Otezla, Repatha |
| Corcept Therapeutics | $18.69 | 2020 | |
| Lilly USA, LLC | $16.47 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $13.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.52 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.